Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

Phase 1 studies with PSI-7851 in the first quarter of 2009;

-- Report interim results from INFORM-1 trial in second quarter of 2009;

-- Report interim results from 28 day add-on study with R7128 in non-responder, HCV genotype 2 and genotype 3 patients in first half of 2009;

-- Report interim results from 28 day add-on study with R7128 in treatment naive, HCV genotype 1 patients in first half of 2009;

-- Report phase 1 antiviral data with PSI-7851 in second half of 2009.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe, among other countries. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. Pharmasset also anticipates initiating phase 1 studies with its second generation nucleotide inhibitor for HCV, PSI-7851 in the first quarter of 2009.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    '/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... 29, 2014  The Society for Clinical Research ... program for the 9 th annual Site ... Amelia Island , Florida.  The focus on ... unchanged, however, the topics and format will allow ... among all stakeholders with a continued focus on ...
(Date:7/29/2014)... July 29, 2014  Discovery Laboratories, Inc. (Nasdaq: ... a new standard of respiratory critical care, will report ... 5, 2014 before the open of the U.S. ... host a live teleconference and webcast at 9:00 a.m. ... call, Discovery Labs, management will discuss the 2014 ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
... 3 VIA Pharmaceuticals,(Nasdaq: VIAP ), a ... the treatment of cardiovascular disease, announced today that,Lawrence ... of VIA, and,James G. Stewart, senior vice president ... at the Seventh Annual Needham & Company,Biotechnology and ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... systems, today announced that President and,Chief Executive Officer Michael ... company,s business outlook, growth strategy and,recent financial results at ... On Thursday, June 12, the company will present at ...
... 3 Masimo Corporation,(Nasdaq: MASI ), the ... announced,that it is scheduled to present at the ... Ritz Carlton, Laguna Nigel, in Dana Point, CA,on ... Joe E. Kiani, Chairman and,CEO, will be presenting., ...
Cached Biology Technology:Cynosure Announces Schedule of Upcoming Investor Conferences 2Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference 2
(Date:7/28/2014)... MIT professor John Essigmann and colleagues from the University of ... thought if they could induce the virus to mutate uncontrollably, ... a strategy that our immune system uses against many ... caused HIV to mutate at an enhanced rate, as expected. ... a small clinical trial reported in 2011. In a new ...
(Date:7/28/2014)... brain cells suggests that the effects of a commonly ... are temporary. , The study, published in this week,s ... conducted by biologists at the University of California, San ... in response to concerns, arising from multiple studies on ... general anesthetics may increase their susceptibility to long-term cognitive ...
(Date:7/28/2014)... of the top 10 U.S. cities that have seen ... inconveniences as frequent road closures, overwhelmed storm drains and ... new NOAA technical report. , This nuisance flooding, caused ... U.S. coasts, between 300 and 925 percent since the ... Flood Frequency Changes around the United States, also finds ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3
... difference between a lifeless sack of chemicals and ... they're organized, according to Stanford biophysical chemist Steven ... California-Davis and Lawrence Livermore National Laboratory, he has ... unprecedented resolution-on the order of 100 nanometers, a ...
... million grant from the National Cancer Institute, a Wake Forest ... the effectiveness of a drug that he developed for the ... M.D., Ph.D., pioneered a method to destroy cells of glioblastoma ... is currently being tested in clinical trials and Debinski is ...
... plumage, flamingos are a curiosity of nature. Now a new ... anatomical oddity that helps flamingos eat: erectile tissue. , Flamingos ... shallow water, they bend their necks, tilt their bills upside ... Their large tongue acts like a piston, sucking water into ...
Cached Biology News:With record resolution and sensitivity, tool images how life organizes in a cell membrane 2With record resolution and sensitivity, tool images how life organizes in a cell membrane 3With record resolution and sensitivity, tool images how life organizes in a cell membrane 4With record resolution and sensitivity, tool images how life organizes in a cell membrane 5With record resolution and sensitivity, tool images how life organizes in a cell membrane 6Scientist works to improve treatment for brain tumors 2Ohio University researchers discover evolutionary oddity in flamingos 2
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
Biology Products: